Clinical trials located in

Aarhus

Aarhus city is located in Denmark. Currently, 20 clinical trials are being conducted in this city.

Aarhus, Denmark’s second-largest city, is a vibrant cultural hub nestled on the Jutland peninsula’s east coast. Founded in the Viking Age, it boasts a rich history evident in landmarks like the Aarhus Cathedral, dating back to the 13th century. The city is renowned for its thriving arts scene, exemplified by the ARoS Aarhus Art Museum, home to the iconic rainbow panorama. Aarhus University, one of Europe’s top institutions, contributes to the city’s lively atmosphere, making it a nexus of education and innovation. The Old Town Open Air Museum (Den Gamle By) offers a unique glimpse into Danish urban history, showcasing over 75 historical buildings from all over the country.

  • CT-EU-00117049

    NCT05280314

    • Pembrolizumab KEYTRUDA®
    • IO102-IO103
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • Exploring encaleret’s effectiveness for Autosomal Dominant Hypocalcemia type 1

    This clinical study is a research project focused on understanding how well and safely a medication called Encaleret works compared to the usual treatments for a condition known as Autosomal Dominant Hypocalcemia Type 1 (ADH1). ADH1 is a rare genetic condition that can lead to low calcium levels in the blood and is often inherited from parents to their children.

    The study is designed to last about 12 months, with an additional option to continue in a longer-term extension for up to 48 months or more, depending on certain conditions. Initially, participants will go through a screening phase to make sure they meet the study requirements.

    Participants will then enter a period where their usual care treatment is maintained, with adjustments only made for safety reasons. Following this, they will be randomly assigned to either continue with their standard care or start taking encaleret. This part of the study allows both the doctors and participants to know which treatment is being used and to adjust the dosage based on blood calcium levels. After 20 weeks, there’s a period to maintain the dose before possibly moving on to the long-term extension phase, where encaleret will be continued.

    The main goal of the study is to see how many participants can reach and maintain their blood and urinary calcium levels within a target range by using encaleret compared to their standard treatments. This is important for managing the symptoms and health risks associated with ADH1.

    This study might be an opportunity for people with ADH1 to try a new treatment option and contribute to research that could help others with the same condition in the future.

    • Encaleret
  • Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    • AZD3427- new potential medication for heart failure and pulmonary hypertension
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • Investigating tirzepatide for kidney disease in overweight people

    In this study, an investigation is being conducted on a medication known as tirzepatide, or LY3298176. The objective is to assess its potential benefits for individuals dealing with overweight or obesity and a chronic kidney condition, which may or may not be associated with type 2 diabetes. The applicability of tirzepatide for individuals in both scenarios is of interest. A specialized imaging technique called BOLD MRI will be utilized to observe kidney activity. The study is designed to span approximately 56 weeks, with participants being requested to attend up to 12 visits in total.

    • Tirzepatide/LY3298176
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    • Sotatercept
  • Testing golcadomide for safety & effectiveness in non-Hodgkin lymphomas

    This trial is about testing the safety and effectiveness of a drug called Golcadomide for people with a certain type of cancer called Non-Hodgkin Lymphomas that has come back or not responded to treatment. This drug can be taken by mouth and will be tested alone or together with other drugs used to treat lymphoma. It is for patients who tried at least two other treatments for their cancer, or if there arent suitable treatment for them. First, different doses of Golcadomide will be given to see which amount can be tolerated without causing too many side effects. Once that’s figured out, the trial will look at how well the chosen dose works either alone or with other lymphoma drugs. The researchersa will also study if eating food together with the drug will affect how the drug works and its safety.

    • Golcadomide/CC-99282
    • Valemetostat
    • Tafasitamab
    • Obinutuzumab
    • Rituximab
  • Study on new medication treatment for adults with Wilson’s Disease

    This study is testing a new type of treatment called VTX-801 for adults who have a disease called Wilson’s Disease. This study will take 5 years and try out different amounts of VTX-801 to see how safe it is and if it helps with the disease. The medicine will be given by a drip. The researchers will stop the usual treatment for Wilson’s Disease while patients are having VTX-801. It’s an open study, so everyone will know they are getting VTX-801 and not a placebo. The researchers will keep track of any bad effects and problems that might happen during the study. The study will take blood tests to see how much copper is in patients’ blood and urine and how this changes over time before and after the study. The researchers will measure if the medicine works by seeing how many people get better with VTX-801.

    • VTX-801
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    • Dupilumab
    • Omalizumab
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • A clinical trial evaluating Baricitinib in young people with juvenile idiopathic arthritis

    This study focuses on systemic Juvenile Idiopathic Arthritis (sJIA) in children aged 1 to less than 18 years old. It aims to evaluate the long-term safety and efficacy of baricitinib, an oral medication. Participants will receive baricitinib daily and undergo regular assessments to monitor the drug’s effectiveness and any adverse effects. Key measures include the number of serious adverse events and the proportion of participants achieving minimal disease activity and remission. The study duration extends to at least 264 weeks, or approximately 5 years.

    • Baricitinib
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of secukinumab treatment for Giant Cell Arteritis

    This study is testing a drug called Secukinumab to see if it is safe and effective in people with a disease known as giant cell arteritis (GCA). GCA affects blood vessels in the body, causing inflammation. In this study, patients will receive Secukinumab or placebo (a treatment without active medicine) along with a medicine called glucocorticoids, the dose of which will be gradually reduced. The test will test whether a 26-week treatment course is more effective than the current 52-week treatment course. The research team will monitor whether the inflammation subsides and does not return throughout the year. The team will also check how long it will take until the disease symptoms return, how many glucocorticosteroids the patient will need within a year and how his quality of life has improved.

    • Secukinumab
  • Testing new medicine for safe treating Chronic Hepatitis B

    This study is about a new drug called IMC-I109V which is meant to help people who have a condition called Chronic Hepatitis B, a long-lasting infection in the liver. The researchers want to see if the new drug is safe, and if it can help to fight off the virus. This is the first time that people will be given this drug, hence why this study is so important. The trial involves different doses of the drug to see which works best and is safest. The researchers will check patient’s vital signs and run lab tests for safety measures.

    • IMC-I109V-101
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    • JNJ-78934804 (guselkumab, golimumab)
    • Golimumab
    • Guselkumab
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    • Apalutamide
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    • Carfilzomib
    • Pomalidomide
    • Teclistamab
    • Dexamethasone
    • Bortezomib

See more clinical trials in other cities in Denmark:

.